Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone201-343-5202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.69 million
Profitability
Miscellaneous
Employees18
Next Earnings DateN/A
OptionableNot Optionable
Nephros (OTCMKTS:NEPH) Frequently Asked Questions
What is Nephros' stock symbol?
Nephros trades on the OTCMKTS under the ticker symbol "NEPH."
How were Nephros' earnings last quarter?
Nephros, Inc. (OTCMKTS:NEPH) released its earnings results on Wednesday, November, 6th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.00. The firm earned $3.10 million during the quarter, compared to analysts' expectations of $3.12 million. Nephros had a negative return on equity of 56.37% and a negative net margin of 49.93%. View Nephros' Earnings History.
What guidance has Nephros issued on next quarter's earnings?
Nephros updated its fourth quarter 2019
Pre-Market earnings guidance on Monday, January, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.2-3.2 million, compared to the consensus revenue estimate of $2.7 million.
What price target have analysts set for NEPH?
3 analysts have issued twelve-month target prices for Nephros' shares. Their forecasts range from $16.00 to $16.00. On average, they anticipate Nephros' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price. View Analyst Price Targets for Nephros.
What is the consensus analysts' recommendation for Nephros?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nephros.
Has Nephros been receiving favorable news coverage?
Media coverage about NEPH stock has been trending positive on Wednesday, according to InfoTrie. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nephros earned a coverage optimism score of 2.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Nephros.
Who are some of Nephros' key competitors?
Some companies that are related to Nephros include Apyx Medical (APYX), Westaim (WEDXF), GenMark Diagnostics (GNMK), Repro-Med Systems (REPR), Repro Med Systems (KRMD), iCAD (ICAD), Venus Concept (VERO), Soliton (SOLY), Vapotherm (VAPO), RenovaCare (RCAR), TELA Bio (TELA), Cytosorbents (CTSO), Pulse Biosciences (PLSE), Liquidia Technologies (LQDA) and BRAINSWAY LTD/S (BWAY).
What other stocks do shareholders of Nephros own?
Who are Nephros' key executives?
Nephros' management team includes the folowing people:
- Mr. Daron G. Evans, Pres, CEO & Director (Age 45)
- Mr. Andrew Astor, CFO & COO (Age 62)
- Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.
Who are Nephros' major shareholders?
Nephros' stock is owned by many different of retail and institutional investors. Top institutional investors include Parkman Healthcare Partners LLC (2.48%), Ingalls & Snyder LLC (1.69%) and National Asset Management Inc. (0.18%). Company insiders that own Nephros stock include Andrew Astor, Daron Evans and Oliver J Spandow. View Institutional Ownership Trends for Nephros.
Which institutional investors are selling Nephros stock?
Which institutional investors are buying Nephros stock?
NEPH stock was purchased by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC and Ingalls & Snyder LLC. Company insiders that have bought Nephros stock in the last two years include Andrew Astor, Daron Evans and Oliver J Spandow. View Insider Buying and Selling for Nephros.
How do I buy shares of Nephros?
Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Nephros' stock price today?
One share of NEPH stock can currently be purchased for approximately $8.88.
How big of a company is Nephros?
Nephros has a market capitalization of $71.56 million and generates $5.69 million in revenue each year. The company earns $-3,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Nephros employs 18 workers across the globe.View Additional Information About Nephros.
What is Nephros' official website?
How can I contact Nephros?
Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202.
MarketBeat Community Rating for Nephros (OTCMKTS NEPH)
MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote "Outperform" if you believe NEPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
